Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques

Contraception

Volumn 81, Issue 4, 2010, Pages 336-342

  Brenner, Robert M ^a   Slayden, Ov D ^a   Nath, Anita ^b   Tsong, Y Y ^b   Sitruk Ware, Regine ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

CDB 2914; Endometrium; Intrauterine; Rhesus macaque; Ulipristal

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; ULIPRISNIL ACETATE; ULIPRISTAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; EPIDERMOID CYST; FEMALE; HISTOLOGY; IMMUNOCYTOCHEMISTRY; MACACA; MENSTRUAL CYCLE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; RHESUS MONKEY; SILASTIC TUBE; STAINING; UTERUS; WEIGHT;

ANIMALS; ATROPHY; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; FEMALE; INTRAUTERINE DEVICES; MACACA MULATTA; MENSTRUATION; NORPREGNADIENES; RECEPTORS, ANDROGEN; UTERUS;

EID: 77949262980     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.11.004     Document Type: Article

References (27)

1. Brenner R.M., and Slayden O.D. Progesterone receptor antagonists and the endometrial antiproliferative effect. Semin Reprod Med 23 (2005) 74-81
2. Chwalisz K., Brenner R.M., Fuhrmann U., Hess-Stumpp H., and Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators (PRMs) on the endometrium. Steroids 65 (2000) 741-751
3. Chwalisz K., Perez M.C., Demanno D., Winkel C., Schubert G., and Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 26 (2005) 423-438
4. Goodman A.L., and Hodgen G.D. Progesterone receptor antagonists. In: Adashi E.Y., Rock J.A., and Rosenwaks Z. (Eds). Reproductive endocrinology, surgery, and technology, Chapter 27 (1996), Lippincott-Raven Publishers, Philadelphia 548-558
5. Elger W., Bartley J., Schneider B., Kaufmann G., Schubert G., and Chwalisz K. Endocrine pharmacological characterization of antiprogestins and progesterone receptor modulators (PRMs) with respect to PR-agonistic and -antagonistic activity. Steroids 65 (2000) 713-723
6. Attardi B.J., Burgenson J., Hild S.A., Reel J.R., and Blye R.P. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188 (2002) 111-123
7. Hild S.A., Reel J.R., Hoffman L.H., and Blye R.P. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 15 (2000) 822-829
8. Blithe D.L., Nieman L.K., Blye R.P., Stratton P., and Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 68 (2003) 1013-1017
9. Gainer E., and Ulmann A. Pharmacologic properties of CDB (VA)-2914. Steroids 68 (2003) 1005-1011
10. Ortiz M.E., Croxatto H.B., and Bardin C.W. Mechanisms of action of intrauterine devices. Obstet Gynecol Survey 51 Suppl (1996) S42-S51
11. McGavigan C.J., and Cameron I.T. The Mirena levonorgestrel system. Drugs Today (Barc) 39 (2003) 973-984
12. Nayak N.R., Slayden O.D., Chwalisz K., Lehtinen M., and Brenner R.M. Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. Contraception 75 (2007) S104-S111
13. Chabbert-Buffet N., Pintiaux-Kairis A., and Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92 (2007) 3582-3589
14. Slayden O.D., Chwalisz K., and Brenner R.M. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod 16 (2001) 1562-1574
15. Slayden O.D., Koji T., and Brenner R.M. Microwave stabilization enhances immunocytochemical detection of estrogen receptor in frozen sections of macaque oviduct. Endocrinology 136 (1995) 4012-4021
16. Petersen R.G. Design and Analysis of Experiments. 66th ed. (1985), Marcel Dekker, Inc., New York
17. Chwalisz K., Garg R., Brenner R., Slayden O., Winkel C., and Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol 4 Suppl 1 (2006) S8
18. Wolf J.P., Hsiu J.G., Anderson T.L., Ulmann A., Baulieu E.E., and Hodgen G.D. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen- stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 52 (1989) 1055-1060
19. Slayden O.D., Nayak N.R., Burton K.A., et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 86 (2001) 2668-2679
20. Narvekar N., Cameron S., Critchley H., LIn S., Cheng L., and Baird D. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 89 (2004) 2491-2497
21. Brenner R.M., Slayden O.D., Nayak N.R., Baird D.T., and Critchley H.O. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids 68 (2003) 1033-1039
22. Brenner R.M., Slayden O.D., and Critchley H.O. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 124 (2002) 167-172
23. Slayden O.D., and Brenner R.M. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 88 (2003) 946-949
24. Baird D.T., Brown A., Critchley H.O., Williams A.R., Lin S., and Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 18 (2003) 61-68
25. Williams A.R., Critchley H.O., Osei J., Ingamells S., et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 22 (2007) 1696-1704
26. Mutter G.L., Bergeron C., Deligdisch L., et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 21 (2008) 591-598
27. Heikinheimo O., Vani S., Carpen O., et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 22 (2007) 2515-2522